Trials / Completed
CompletedNCT05149378
Venetoclax Based Regimen for R/R T-ALL
Venetoclax Based Regimen for the Treatment of Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- The First Affiliated Hospital of Soochow University · Academic / Other
- Sex
- All
- Age
- 15 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is to investigate the therapeutic efficacy and side effect of venetoclax based regimen for relapsed or refractroy T cell acute lymphoblastic leukemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Venetoclax combined with azacitidine regimen | Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); azacitidine 75 mg/m2 subcutaneously once daily on days 1-7 . |
Timeline
- Start date
- 2021-11-01
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
- First posted
- 2021-12-08
- Last updated
- 2025-05-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05149378. Inclusion in this directory is not an endorsement.